Baseline characteristics of the stabilized IPTW analysis study cohorts (sensitivity analysis)
| . | Rivaroxaban, % (N = 533) . | LMWH, % (N = 1223) . | Standardized difference . |
|---|---|---|---|
| Demographics | |||
| Age ≥75 y | 40.3 | 39.5 | 0.016 |
| Female sex | 72.1 | 72.0 | 0.001 |
| White race | 78.5 | 78.3 | 0.005 |
| Index event PE (with or without DVT) | 49.4 | 49.8 | −0.009 |
| Index DVT only | 50.6 | 50.2 | 0.009 |
| Primary cancer site | |||
| Breast | 29.9 | 29.0 | 0.018 |
| Lung | 44.1 | 43.8 | 0.006 |
| Ovary | 7.0 | 7.1 | −0.004 |
| Pancreas | 15.2 | 15.7 | −0.013 |
| Other | 3.9 | 4.5 | −0.027 |
| Cancer stage at diagnosis* | |||
| Stage II or III | 98.5 | 0.006 | |
| Stage I or IV or unknown | † | ||
| Time from first cancer diagnosis to index VTE, y‡ | |||
| <1 | 62.6 | 62.6 | 0.001 |
| 1 to <2 | 12.5 | 12.6 | −0.002 |
| 2 to <3 | 7.5 | 7.5 | 0 |
| ≥3 | 17.4 | 17.4 | 0 |
| Comorbidities and medications | |||
| Active cancer therapy | 69.9 | 69.9 | 0 |
| Antiplatelet use | 6.4 | 6.3 | 0.004 |
| CKD stage 3 or worse | 31.5 | 32.4 | −0.019 |
| Coagulopathy | 9.7 | 10.0 | −0.01 |
| Major bleed | † | † | −0.044 |
| Prior VTE | 24.1 | 24.1 | 0.001 |
| Surgery within 2 wk prior to index event | 2.9 | 3.0 | −0.007 |
| Thrombocytopenia | 6.4 | 6.9 | −0.023 |
| . | Rivaroxaban, % (N = 533) . | LMWH, % (N = 1223) . | Standardized difference . |
|---|---|---|---|
| Demographics | |||
| Age ≥75 y | 40.3 | 39.5 | 0.016 |
| Female sex | 72.1 | 72.0 | 0.001 |
| White race | 78.5 | 78.3 | 0.005 |
| Index event PE (with or without DVT) | 49.4 | 49.8 | −0.009 |
| Index DVT only | 50.6 | 50.2 | 0.009 |
| Primary cancer site | |||
| Breast | 29.9 | 29.0 | 0.018 |
| Lung | 44.1 | 43.8 | 0.006 |
| Ovary | 7.0 | 7.1 | −0.004 |
| Pancreas | 15.2 | 15.7 | −0.013 |
| Other | 3.9 | 4.5 | −0.027 |
| Cancer stage at diagnosis* | |||
| Stage II or III | 98.5 | 0.006 | |
| Stage I or IV or unknown | † | ||
| Time from first cancer diagnosis to index VTE, y‡ | |||
| <1 | 62.6 | 62.6 | 0.001 |
| 1 to <2 | 12.5 | 12.6 | −0.002 |
| 2 to <3 | 7.5 | 7.5 | 0 |
| ≥3 | 17.4 | 17.4 | 0 |
| Comorbidities and medications | |||
| Active cancer therapy | 69.9 | 69.9 | 0 |
| Antiplatelet use | 6.4 | 6.3 | 0.004 |
| CKD stage 3 or worse | 31.5 | 32.4 | −0.019 |
| Coagulopathy | 9.7 | 10.0 | −0.01 |
| Major bleed | † | † | −0.044 |
| Prior VTE | 24.1 | 24.1 | 0.001 |
| Surgery within 2 wk prior to index event | 2.9 | 3.0 | −0.007 |
| Thrombocytopenia | 6.4 | 6.9 | −0.023 |
In the match analysis, stages I, II, III, and IV and unknown were all matched separately.
Data not reported or reported for the entire study cohort, to comply with the Cell Size Suppression Policy of the Centers for Medicare and Medicaid Services (available at: https://www.resdac.org/articles/cms-cell-size-suppression-policy). Variables were included in the propensity score–matching algorithm, as depicted in the table.
Patients may have had subsequent relapse or new metastatic disease.